Manasi Vaidya

1 month ago | pharmaceutical-technology.com | Manasi Vaidya

While pharma manufacturing deals in the US increased, large cuts to research and regulatory agencies increased concerns for the sector. President Donald Trump speaks during a rally at Macomb Community College on 29 April at Warren, Michigan, touting his accomplishments in the first 100 days of his presidency. Image credit: Getty Images / Scott Olson / Staff.

1 month ago | clinicaltrialsarena.com | Jenna Philpott |Abigail Beaney |Manasi Vaidya

The US government has signalled a major shift in its trade policies in recent weeks, with several announcements detailing plans for import tariffs. While President Trump has made several announcements on tariffs since he took office, things accelerated on 2 April, which was christened as ‘Liberation day’ when the administration announced reciprocal tariffs for a number of countries.

2 months ago | clinicaltrialsarena.com | Manasi Vaidya

As advocacy efforts bolster the need for patient-focused drug development, amidst regulatory encouragement, the value of listening to patients is being realised in a more actionable manner. “You can paint a fuller picture by hearing directly from patients,” said Richie Kahn, co-founder and COO of Canary Advisors. Kahn was speaking at the ongoing Outsourcing in Clinical Trials Southeast 2025 conference, being held 1–2 April in Cary, North Carolina.

Mar 7, 2025 | clinicaltrialsarena.com | Manasi Vaidya

As patient voices get amplified across platforms, finding effective ways to further enhance participation and let patient-driven inputs drive clinical research is becoming increasingly important. An upcoming conference is set to explore this and other issues relevant to participants and sponsors who drive clinical research at pharma and biotech companies and research institutions.

Jan 13, 2025 | pharmaceutical-technology.com | Manasi Vaidya

After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotech’s current shareholders. Eli Lilly has announced plans to acquire Scorpion Therapeutics’ PI3Kα inhibitor program. Credit: Michael Vi via Shutterstock. Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets.